deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT03341156

Administration of Prothrombin Complex Concentrate vs. Standard Transfusion During/After Heart Transplantation (OPSTAHT)

Optimized Administration of Prothrombin Complex Concentrate (PCC) vs. Standard Transfusion During/After Heart Transplantation - OPSTAHT

Sponsor: CSL Behring

Conditions Heart Disease End Stage Heart Failure，Congestive
Interventions Frozen Plasma Product, Human Kcentra
Updated 16 times since 2017 Last updated: May 19, 2025 Started: Jul 11, 2018 Primary completion: Sep 18, 2020 Completion: Feb 20, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Standard practice change prohibited enrollment

Other terminated trials from CSL Behring

See all terminations from CSL Behring

Listed as NCT03341156, this PHASE3 trial focuses on Heart Disease End Stage and Heart Failure，Congestive and remains terminated or withdrawn. Sponsored by CSL Behring, it has been updated 16 times since 2018, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~May 2019 · 6 months · monthly snapshot~May 2019 – ~Sep 2019 · 4 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Nov 2020 · 12 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Feb 2022 · 4 months · monthly snapshot~Feb 2022 – ~Dec 2022 · 10 months · monthly snapshot~Dec 2022 – ~Aug 2023 · 8 months · monthly snapshot~Aug 2023 – ~Feb 2024 · 6 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – present · 13 months · monthly snapshot

Change History

16 versions recorded

  1. Jun 2025 — Present [monthly]

    Terminated PHASE3

    Status: Recruiting → Terminated

  2. Sep 2024 — Jun 2025 [monthly]

    Recruiting PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

  4. Feb 2024 — Jul 2024 [monthly]

    Recruiting PHASE3

  5. Aug 2023 — Feb 2024 [monthly]

    Recruiting PHASE3

▶ Show 11 earlier versions

  1. Dec 2022 — Aug 2023 [monthly]

    Recruiting PHASE3

  2. Feb 2022 — Dec 2022 [monthly]

    Recruiting PHASE3

  3. Oct 2021 — Feb 2022 [monthly]

    Recruiting PHASE3

  4. Jan 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

  5. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  6. Nov 2019 — Nov 2020 [monthly]

    Recruiting PHASE3

  7. Sep 2019 — Nov 2019 [monthly]

    Recruiting PHASE3

  8. May 2019 — Sep 2019 [monthly]

    Recruiting PHASE3

  9. Nov 2018 — May 2019 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  10. Jun 2018 — Nov 2018 [monthly]

    Not Yet Recruiting PHASE3

  11. Dec 2017 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • CSL Behring
  • University of Maryland, Baltimore
Data source: University of Maryland, Baltimore

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations